Copyright
©The Author(s) 2021.
World J Clin Cases. Dec 26, 2021; 9(36): 11285-11299
Published online Dec 26, 2021. doi: 10.12998/wjcc.v9.i36.11285
Published online Dec 26, 2021. doi: 10.12998/wjcc.v9.i36.11285
Table 2 Clinical characteristics of study patients at baseline, n (%)
| Overall (n = 220) | CD (n = 133) | UC (n = 87) | |
| Endoscopic findings (presence and size of ulcers) | |||
| Unaffected | 9 (4) | 7 (5) | 2 (2) |
| Mild (1-5 mm) | 7 (3) | 1 (1) | 6 (7) |
| Moderate (5-20 mm) | 54 (25) | 21 (16) | 33 (38) |
| Severe (> 20 mm) | 41 (19) | 25 (19) | 16 (18) |
| Fibrotic stenosis | 7 (3) | 7 (5) | 0 (0) |
| Not performed | 102 (46) | 72 (54) | 30 (34) |
| Ultrasound findings (hyperemia of the bowel wall assessed by color Doppler ultrasound) | |||
| Unaffected | 5 (2) | 5 (4) | - |
| Mild (2 signal dots/cm2) | 7 (3) | 7 (5) | - |
| Moderate | 34 (26) | - | |
| (3-5 signal dots/cm2) | 34 (15) | ||
| Severe (> 5 signal dots/cm2) | 22 (10) | 22 (17) | - |
| Not performed | 152 (69) | 65 (49) | 87 (100) |
| Previous treatments | |||
| Mesalazine | 97 (44) | 37 (28) | 60 (69) |
| Corticosteroids | 131 (60) | 73(55) | 58 (67) |
| AZA/6-MP | 135 (61) | 82 (62) | 53 (61) |
| MTX | 12 (5) | 10 (8) | 2 (2) |
| Remicade® | 35 (16) | 21 (16) | 14 (16) |
| Humira® | 22 (10) | 15 (11) | 7 (8) |
| Concomitant treatments | |||
| Mesalazine | 77 (35) | 28 (21) | 49 (56) |
| Corticosteroids | 74 (35) | 37 (28) | 37 (43) |
| AZA/6-MP | 115 (52) | 67 (50) | 48 (55) |
| MTX | 15 (7) | 15 (11) | 0 (0) |
- Citation: Huguet JM, Cortés X, Bosca-Watts MM, Aguas M, Maroto N, Martí L, Amorós C, Paredes JM. Real-world data on the infliximab biosimilar CT-P13 (Remsima®) in inflammatory bowel disease. World J Clin Cases 2021; 9(36): 11285-11299
- URL: https://www.wjgnet.com/2307-8960/full/v9/i36/11285.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v9.i36.11285